LEGN Stock Summary and Trading Ideas (Legend Biotech - American Depositary Shares | NASDAQ:LEGN)

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.

As of February 9, 2026, LEGN stock price climbed to $17.19 with 3,459,022 million shares trading.

LEGN has a beta of 0.50, meaning it tends to be less sensitive to market movements. LEGN has a correlation of 0.03 to the broad based SPY ETF.

LEGN has a market cap of $3.15 billion. This is considered a Mid Cap stock.

Last quarter Legend Biotech - American Depositary Shares reported $272 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.07.

In the last 3 years, LEGN traded as high as $77.32 and as low as $16.24.

The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, MCHI, EEM, KOMP.

LEGN has underperformed the market in the last year with a price return of -52.4% while the SPY ETF gained +15.7%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.9% and -9.6%, respectively, while the SPY returned +3.8% and +0.7%, respectively.

LEGN support price is $16.45 and resistance is $17.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.